This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.
CONFIRM

ACC

Uniting Antibodies and Cell Therapy to Fight Cancer

Acepodia is developing potent, off-the-shelf targeted cancer cell therapies that unlock the immune system’s ability to fight both solid tumors and hematological malignancies.

Antibody-Cell Conjugation (ACC) technology uses live-cell compatible chemistry to link any tumor-targeting antibody to the surface of human immune cells. This powerful, new approach to cell therapy development has the potential to dramatically enhance the ability of oNK cells and γδ2 T cells to recognize and engage the tumor by unlocking multiple receptor signaling pathways. This could potentially allow ACC-γδ2 T and oNK therapies to overcome the challenges that have prevented cell therapies from effectively targeting solid tumors.

未命名-1
PLAY VIDEO
Applying The ACC Approach
Highly Versatile and Broadly Applicable

Highly Versatile and Broadly Applicable

In addition to the benefits of potency conferred by ACC, its simplicity and modular “plug and play” nature could make cell therapies more accessible to patients and allows for the expansion into other indications beyond oncology and other immune cells.
In the Clinic: ACC candidate for HER2-Expressing Solid Tumors

In the Clinic: ACC candidate for HER2-Expressing Solid Tumors

Acepodia’s lead clinical candidate, ACE1702, is a HER2-targeting ACC-oNK cell therapy developed for the treatment of HER2-expressing cancers including breast, endometrial and colorectal cancers.

ACE1702 is being evaluated in a Phase 1 clinical trial which is currently enrolling patients in the U.S. and Taiwan.
In the Clinic: ACC candidate for non-Hodgkin’s lymphoma

In the Clinic: ACC candidate for non-Hodgkin’s lymphoma

Acepodia’s second clinical candidate, ACE1831, is a CD20-targeting ACC- gamma delta2 (γδ2) T cell therapy developed for the treatment of relapsed / refractory non-Hodgkin’s lymphoma including Diffuse large B-cell lymphoma, Marginal zone lymphoma..etc.

ACE1831 is obtained IND clearance for Phase 1 clinical trial which will enroll patients in the U.S. and Taiwan.

Potent, Off-the-Shelf Cell Lines as the Chassis for our ACC Technology

In order to develop the most effective immunotherapies possible, Acepodia equips its ACC technology to both of its proprietary gamma delta2 (γδ2) T cells and off-the-shelf NK (oNK) cells which are allogeneic, and specially selected for enhanced tumor engagement. ACC allows for any antibody, new or existing, to be conjugated to the stimulatory surface receptors of these immune cells to yield the additive effect of superior tumor targeting to our already potent and off-the-shelf biologic drug payloads.

PIPELINE

PROMISING PIPELINE OF CELL THERAPIES

ACC-γδ2 T

Program
Discovery
Preclinical
Phase I
Phase II
ACE1831
CD20 Targeting, ACC-γδ2 T Cell Therapy
Phase I ​
ACE2016
EGFR Targeting, ACC-γδ2 T Cell Therapy
Preclinical ​
ACE1708
PD-L1 Targeting, ACC-γδ2 T Cell Therapy
Discovery ​
ACE1975
Target undisclosed, ACC-γδ2 T Cell Therapy
Discovery ​
ACE2023
Target undisclosed, ACC-γδ2 T Cell Therapy
Discovery ​

ACC-oNK

Program
Discovery
Preclinical
Phase I
Phase II
ACE1702
HER2 Targeting, ACC-oNK Cell Therapy
Phase I ​
We have collaborated with biopharmaceutical partners and academic institutes worldwide.